Everyday Urology™ – Oncology Insights: From the Editor
From the Desk of the Editor: Volume 5, Issue 3
This issue's cover story is written by Patrick J. Hensley, MD, Urological Oncology Fellow, and world-renowned urologist, Ashish M. Kamat from the University of Texas MD Anderson Cancer Center, Houston, Texas, entitled: “Overcoming Diagnostic and Therapeutic Challenges in Non-muscle Invasive Bladder Cancer (NMIBC)”. In 2020, approximately 81,000 cases of urothelial carcinoma of the bladder will be diagnosed in the United States, with nearly 18,000 associated deaths.¹ In their review article, Drs. Kamat and Hensley discuss current challenges in NMIBC, emerging diagnostic approaches, and advances in both intravesical and systemic therapy.
Sam S. Chang, MD, MBA, provides a concise and well-balanced update on low-grade upper tract urothelial carcinoma in the expert perspective article. Upper tract urothelial carcinomas (UTUCs) are a heterogeneous group of malignancies arising from the urothelium within the renal pelvis or upper ureter.
From the Desk of the Editor: Volume 5, Issue 2
Welcome to the second issue of Everyday Urology – Oncology Insights of 2020, published by Digital Science Press. Throughout the year, UroToday.com has provided information and expert perspectives on the evolving state of urology and GU oncology, as well as the impact COVID-19 has had on the healthcare environment, featuring video discussions amongst physicians at the frontlines of care and research. These videos, along with discussions of conference updates, journal clubs and the cancer patient journey series are featured on the UroToday.com website. This issue focuses on advances in the management of prostate cancer, as well as the ASCO 2020 virtual meeting held May 29-31, 2020.
In their article, “What is Changing in Advanced Prostate Cancer?” Christopher J.D. Wallis, MD, Ph.D., and Zachary Klaassen, MD, profile the ways in which advanced prostate cancer treatment has been revolutionized over the last 15 years, as no less than nine novel agents have been introduced with proven overall survival benefits. Reviewing the evidence that has defined these changes, Dr. Wallis and Dr. Klaassen detail the pivotal trials and FDA approvals that have demonstrated survival benefits across metastatic castration-resistant prostate cancer (mCRPC), metastatic castration sensitive prostate cancer (mCSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), beginning with the introduction of docetaxel for men with castration-resistant prostate cancer in 2004, and continuing through recent phase 3 trials as well as reviewing novel treatment strategies.
From the Desk of the Editor: Volume 5, Issue 1
Welcome back to another issue of Everyday Urology - Oncology Insights, the first issue of 2020 brought to you by UroToday. In the featured articles of this issue, we highlight the work of Edward Schaeffer, MD, PhD, and Ashley Baker, MD, presentations as well as work from Noah Hahn, MD, in a presentation I stepped in and gave at the 2019 Large Urology Group Practice Association (LUGPA) Continued Medical Education (CME) Program. This meeting’s agenda collectively focused on Leveraging Disruptive Technology: Pragmatic and Productive Advances for your Practice, which included a variety of presentations in prostate, bladder, and renal cancers as well as bladder health, minimally invasive procedures and preparing your clinics for the evolving future.
At the 2019 LUGPA CME, Dr. Edward Schaeffer presented on the relevancy of traditional culture testing in urinary tract infections (UTIs). Given the varying degree of complication associated with UTIs, Dr. Schaeffer highlights the available options for testing and treatment. He concludes by dissecting the benefits and pitfalls of a few of his most recommended tests and points out that clinical outcomes will ultimately depend on the nuances of symptoms that result from a host’s response to bacteria.
From the Desk of the Editor: Volume 4, Issue 4
From the Desk of the Editor: Volume 4, Issue 3
Welcome back to Everyday Urology - Oncology Insights. As is our journal’s goal, this issue will illuminate recent advances within the management armamentarium of Urologic Oncology by featuring clinical care updates and expert opinions. In this issue, Everyday Urology focuses on advanced prostate cancer, highlighting recent additions to the nmCRPC treatment landscape as well as the emerging role of theranostics. Finally, our spotlight features coverage of the Advanced Prostate Cancer Consensus Conference, (APCCC 2019) held August 29 - 31, 2019 in Basel, Switzerland.
From the Desk of the Editor: Volume 4, Issue 2
From the Desk of the Editor: Volume 4, Issue 1
From the Desk of the Editor: Volume 3, Issue 4
From the Desk of the Editor: Volume 3, Issue 3
From the Desk of the Editor: Volume 3, Issue 2
Welcome to Volume 3, Issue 2 of Everyday Urology – Oncology Insights. This edition’s cover story by Phillip Koo, MD, Imaging Controversies for Localized and Advanced Prostate Cancer explores the challenging topic of imaging modalities for Prostate Cancer. He discusses the use of multiparametric magnetic resonance imaging (mpMRI) as well as positron emission tomography-computed tomography (PET/CT), C-11 Choline, and 18F-Fluciclovine for both localized and advanced prostate cancer disease management. Dr. Koo also reviews the ability of scoring systems, such as the Prostate Imaging Reporting and Data System (PIRADS) as well as similar tools to enhance stratification assessments and interdisciplinary communication.
From the Desk of the Editor: Volume 3, Issue 1
From the Desk of the Editor: Volume 2, Issue 4
From the Desk of the Editor: Volume 2, Issue 3
Petros Grivas’ cover article, Updates on Immunotherapy for Urothelial Cancer, not only succinctly reviews the five new approved immuno-oncology therapies (IO), aka checkpoint (PD pathway) inhibitors and their milestone clinical trials, but also offers guidance regarding treatment selection strategy as well as IO selection within the context of chemotherapeutic options. Additionally, he discusses a basis for monitoring efficacy of response, potential biomarkers and genomic markers predictive of patient benefit and also reviews the ongoing possibilities for combination strategies. Clearly, both advanced bladder and kidney cancer care information and subsequent
From the Desk of the Editor: Volume 2, Issue 2
From the Desk of the Editor: Volume 2, Issue 1
Our first issue of 2017 emphasizes a well-known, yet an evolving and important, theme: optimizing the successful multidisciplinary collaboration amongst oncologic physicians; and furthermore, the importance of patient involvement, also known as, patient-physician shared decision making (and assuredly, successful integrated care). This multidimensional approach to decision making and treatment has numerous advantages in all phases of the patient care experience, the physician expectation of successful genitourinary oncology outcomes, and efficiency for the healthcare ecosystem. The authors of our three featured articles in this issue include the specialties of: urology, cardiology and nuclear medicine.